New Pharmaceutical Company to Target Alzheimer's Disease
News Oct 23, 2008
A team of world-renowned scientists has announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease.
Archer Pharmaceuticals, Inc., led by Chief Executive Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer Fiona Crawford, Ph.D., was created based on the research that their team has been conducting in Florida for the past five years.
Archer Pharmaceuticals, Inc. has several compounds that are ready to enter clinical development, including ARC029 and ARC031. These compounds have been manufactured at the Sarasota-based facility to U.S. Food and Drug Administration (FDA) regulatory standards (GMP).
Both are targeted at the reduction of soluble amyloid proteins in the brain - thought by many to be the main culprits in degeneration of neurons in the brains of Alzheimer's disease sufferers.
In addition, Archer Pharmaceuticals, Inc. has several other agents in the preclinical stage, including Gamma Secretase Inhibitors and BACE Inhibitors. These approaches are designed to attack the Alzheimer's disease soluble amyloid in different ways, providing complementary approaches to the lead compounds.
ARC029 was selected from approximately 2,000 agents as Archer Pharmaceuticals, Inc.'s first-line treatment for Alzheimer's because it was one of the most proficient at lowering amyloid levels in preclinical models. In these models ARC029 reduces brain amyloid levels by largely unexplored biological mechanisms.
"ARC029 acts to lower the soluble forms of amyloid before they damage the brain's neurons," said Dr. Mullan. "We believe that the soluble, rather than the deposited forms, are the real culprits in the disease, and so reducing them is our goal with this compound."
"Alzheimer's disease is a growing problem around the world, with devastating consequences for patients, caregivers and families," said Dr. Crawford. "We now have strategies to tackle the cause, not just the consequences, of Alzheimer's disease. We are confident that the expertise and dedication of the Archer staff will lead to effective treatments for this terrible disease."
A Phase I/IIA clinical trial that is currently being conducted in Europe was designed to evaluate the safety of Nilvadipine, the active ingredient of ARC029, in Alzheimer's sufferers. The study has shown that the drug was well tolerated in Alzheimer's patients.
While neither ARC029 nor ARC031 is currently available in the United States (U.S.), Archer Pharmaceuticals, Inc. is expecting to proceed with U.S. clinical studies within the next few months.
Archer Pharmaceuticals, Inc. intends to fast track ARC029 and ARC031, while continuing to work on other therapeutic approaches.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Molecule Prevents Common Cold Virus from Hijacking Human CellsNews
Researchers have lab-tested a molecule that can combat the common cold virus by preventing it from hijacking human cells.READ MORE
Improving Pharmaceuticals: Catalyst Specifically Tuned to Integrate Fluorine AtomsNews
In the race to create more potent and stable medicines, scientists know that adding fluorine can improve drug molecules. However, there is only one fluorination reaction known to occur in nature which is performed by complex and highly specialized enzymes that are difficult to replicate. Now, scientists have developed a new, streamlined molecule that can do the work of enzymes but be designed and controlled minutely.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018